Drug Price Trends for ROBAFEN DM

Average Pharmacy Cost for ROBAFEN DM

These are average pharmacy acquisition costs (net of discounts) from a US national survey

Drug Name	NDC	Price/Unit ($)	Unit	Date
ROBAFEN DM 200-20 MG/20 ML LIQ	00904-7441-20	0.01866	ML	2024-12-25
ROBAFEN DM 200-20 MG/20 ML LIQ	00904-7223-20	0.01866	ML	2024-12-18
ROBAFEN DM 200-20 MG/20 ML LIQ	00904-7223-59	0.01668	ML	2024-12-18
ROBAFEN DM 200-20 MG/20 ML LIQ	00904-7223-20	0.01825	ML	2024-11-20

ROBAFEN DM Market Analysis and Financial Projection

Market Analysis and Price Projections for Robafen DM

Overview of Robafen DM

Robafen DM is a non-drowsy, over-the-counter (OTC) medication designed to relieve cough and chest congestion. It contains two active ingredients: dextromethorphan hydrobromide, a cough suppressant, and guaifenesin, an expectorant. This combination helps to temporarily relieve coughs due to minor throat and bronchial irritation, such as those occurring with a cold, and aids in loosening phlegm and thinning bronchial secretions[1].

Market Size and Growth

The global dextromethorphan market, which includes products like Robafen DM, was valued at USD 487.25 million in 2022. It is projected to grow to USD 587.31 million by 2030, with a Compound Annual Growth Rate (CAGR) of 4.8% during the forecast period of 2023 to 2030. The OTC segment dominates this market due to high demand for self-medication and easy accessibility of these products[2].

Drivers of Market Growth

Increasing Prevalence of Cough-Related Conditions

The rising prevalence of respiratory conditions such as the common cold, flu, bronchitis, and allergies drives the demand for cough medications. As these conditions are common and recurring, the need for effective cough suppressants and expectorants like Robafen DM continues to grow[2].

Growing Consumer Awareness and Self-Medication

Increased access to healthcare information has led to greater consumer awareness and a preference for self-medication. This trend is particularly significant for OTC medications, as consumers are more likely to seek relief from cough symptoms using products like Robafen DM[2].

Growing Investment in Healthcare Facilities

Improvements in healthcare infrastructure and investments in research and development also contribute to the growth of the dextromethorphan market. These advancements enhance the overall quality and availability of healthcare products, including cough medications[2].

Technological Advancements

Innovations in Drug Delivery Systems

Technological advancements in drug delivery systems, such as improved formulations and combination products, have enhanced the efficacy and convenience of cough medications. These innovations make products like Robafen DM more appealing to consumers, contributing to market expansion[2].

Market Segmentation

Product Type

The global dextromethorphan market is segmented by product type, with OTC products being the dominant segment. Robafen DM, as an OTC medication, benefits from this trend[2].

Age Group

The market is also segmented by age group, with adult products like Robafen DM being widely used. This product is not intended for children under 12 years of age, which aligns with the adult-focused segment of the market[1][2].

Dosage Form

Robafen DM is available in a liquid form, which is one of the common dosage forms in the dextromethorphan market. Other forms include syrups and tablets, but the liquid form remains popular for its ease of administration[1][2].

Price Projections

Current Pricing

As of the current data, Robafen DM is priced around $0.09 per unit for a 118 milliliter quantity, totaling approximately $10.05. This pricing is competitive within the OTC cough medication market[5].

Future Pricing Trends

Given the projected growth of the dextromethorphan market, prices for Robafen DM and similar products are likely to remain stable or see moderate increases. Factors influencing price include production costs, regulatory changes, and market competition.

Competitive Landscape

The market for cough medications is highly competitive, with several brands offering similar products. For example, the recall of Robitussin Honey CF Max products due to microbial contamination could potentially shift consumer preference towards other brands like Robafen DM, affecting pricing dynamics[4].

Regional Market Analysis

North America

North America dominates the global dextromethorphan market due to a strong base of healthcare facilities and significant research activities. This region is expected to continue driving demand for products like Robafen DM[2].

Asia-Pacific

The Asia-Pacific region is anticipated to witness significant growth during the forecast period. This growth is driven by government initiatives, increasing healthcare facilities, and a large population pool seeking quality healthcare. This expansion could lead to increased demand and potentially stable or slightly increased prices for Robafen DM in these markets[2].

Challenges and Restraints

Rising Competition

The dextromethorphan market faces rising competition from both local and global brands. This competition can impact pricing strategies and market share for products like Robafen DM[2].

Regulatory Framework

Regulatory changes and recalls, such as the recent recall of Robitussin products, can affect consumer trust and market dynamics. Manufacturers must adhere to strict quality standards to maintain market confidence and avoid recalls that could impact pricing and sales[4].

Key Takeaways

• Market Growth: The global dextromethorphan market is expected to grow at a CAGR of 4.8% from 2023 to 2030.
• Product Demand: Increasing prevalence of cough-related conditions and growing consumer awareness drive demand for OTC medications like Robafen DM.
• Technological Advancements: Innovations in drug delivery systems enhance the efficacy and convenience of cough medications.
• Pricing Trends: Prices are likely to remain stable or see moderate increases due to market competition and regulatory factors.
• Regional Growth: North America and the Asia-Pacific region are key markets driving demand for Robafen DM.

FAQs

What are the active ingredients in Robafen DM?

Robafen DM contains dextromethorphan hydrobromide (10 mg in 5 mL) as a cough suppressant and guaifenesin (200 mg in 5 mL) as an expectorant[1].

What are the common uses of Robafen DM?

Robafen DM is used to temporarily relieve cough due to minor throat and bronchial irritation and to help loosen phlegm and thin bronchial secretions[1].

Can children use Robafen DM?

No, Robafen DM is not intended for use in children under 12 years of age[1].

What is the projected market size for the global dextromethorphan market by 2030?

The global dextromethorphan market is expected to reach USD 587.31 million by 2030[2].

Why is the dextromethorphan market growing?

The market is growing due to increasing prevalence of cough-related conditions, growing consumer awareness and self-medication practices, and advancements in healthcare infrastructure and drug delivery systems[2].

What are the potential risks associated with using Robafen DM?

While generally safe, consumers should follow the recommended dosage and be aware of potential interactions with other medications. It is also important to note any recalls or safety alerts related to similar products[1][4].

Sources

1. Drugs.com: Robafen DM Max Non drowsy (liquid) Major Pharmaceuticals.
2. Data Bridge Market Research: Global Dextromethorphan Market – Industry Trends and Forecast to 2030.
3. WellRx: Robafen Dm Side Effects, Uses, Interactions, Pictures, Warnings.
4. FDA: Haleon Issues Voluntary Nationwide Recall of Robitussin Honey CF Max Day Adult and Robitussin Honey CF Max Nighttime Adult.
5. Drugs.com: Robafen Prices, Coupons, Copay Cards & Patient Assistance.